Amarillo Biosciences to Reaffirm Low-Dose Interferon Research Leadership Position and Global Commitment to Support Related Therapeutics

Amarillo, Texas, Aug. 13, 2020 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE -- Amarillo Biosciences, Inc. (“ABI” or the “Company”), (AMAR), a diversified healthcare company, today announced that it is taking steps to reaffirm its position as the world leader in low-dose non-injectable interferon research.  ABI will strengthen its commitment to bring its products to market by supporting global advancement of its therapeutics with other like-minded biopharma industry partners.

Since its inception in 1984, ABI has been the leading pioneer in the research of low-dose non-injectable interferon (IFN) delivered through nasal, oral mucosal, topical and transdermal pathways, either in liquid, ointment or lozenge form.  The company’s drug development program, VELDONA (Very Low-Dose Oral Interferon Alpha), encompasses the most comprehensive library of scientific clinical data for low-dose interferon having completed more than 100 pre-clinical animal and human studies on its safety and efficacy over the course of thirty-five years.  ABI also has an accomplished track record of completing well over 60 clinical trials for numerous disease indications, with many reaching phase II and phase III trials.  Historically, the company has focused on R&D involving low-dose, orally administered patented lozenges containing the natural immune system activator interferon alpha (IFN-α) as a treatment for numerous human disease indications such as influenza, hepatitis C, thrombocytopenia, HIV, SARS and other conditions ranging from genital warts to canker sores.

Since the occurrence of Covid-19, there have been no drugs approved for administration early in the stages of infection or for preventive administration to those at high risk.  However, positive data from laboratory research and clinical trials using recombinant IFN, either alone or in combination with other antivirals, indicate IFN as an attractive therapeutic option.  Researchers have valid concerns regarding the side effects and pro-inflammatory effects resulting from high-dose injectable IFN used in many of these recent studies.  This is a debilitating problem common among high-dose IFN injectable treatments that highlights the significance of exploring low-dose IFN in further research and also underscores the importance of leveraging ABI’s extensive clinical research to expedite clinical trials.